CJC-1295 with DAC 2mg (Sinoway)

Manufacturer: Sinoway

Pharmaceutical name: Drug Affinity Complex: Growth Hormone-Releasing Factor

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic version of a segment of the naturally occurring growth hormone releasing hormone (GHRH). The CJC-1295 with DAC peptide is constructed around the initial 29 amino acids of endogenously produced GHRH, as these first 29 residues are essential for full biological activity.

However, this peptide has been enhanced by replacing four amino acids, which boosts its stability and efficacy compared to the earlier version of CJC-1295 without DAC. These substitutions enable the peptide to permanently attach to the protein albumin within the body, thereby minimizing its degradation and oxidation, which contributes to its stability. Moreover, these extra amino acids enhance the binding affinity to the GHRH receptor, increasing its potency. GHRH plays a crucial role in the natural secretion of growth hormone and is vital for achieving optimal growth during development.

CJC-1295 operates by stimulating the release of growth hormone through its binding to GHRH receptors, which should activate the secretion of the complete array of growth hormone peptides typically released by the pituitary gland. These hormones promote increases in bone density and collagen synthesis, while also boosting the immune system. Additionally, they encourage the development of lean muscle mass.

CJC-1295 with DAC can be synergistically used with growth hormone releasing peptides for improved cycling outcomes. It is frequently combined with growth hormone replacement peptides (GHRP) such as GHRP-6 or GHRP-2. The combined application of CJC-1295 DAC with GHRPs can expedite fat loss and weight reduction while inducing anabolic effects by facilitating fat breakdown through growth hormone. Overall, CJC-1295 with DAC will enhance protein synthesis and support the growth of lean muscle tissue. The peptide also encourages quicker recovery from injuries, decreases body fat, and enhances muscle mass. Its growth-stimulating effects will further promote cell growth and division, enhancing skin health, healing, and immune function.

This peptide should not be mistaken for CJC-1295 without DAC, as their chemical properties differ significantly, which influences dosing. CJC-1295 DAC has an approximate half-life of 8 days post-injection. CJC-1295 with DAC should be administered subcutaneously, with injections occurring once a week at dosages of 100 mcg or 200 mcg, thanks to its prolonged half-life. This CJC-1295 DAC cycling regimen will provide a sustained increase in growth hormone levels. A weekly injection of CJC-1295 with DAC can be combined (stacked) with other GHRPs, such as GHRP-6 or GHRP-2.

Numerous studies have documented the growth-promoting benefits and safety of administering GHRH to children with growth hormone deficiencies. Various treatment methods, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusions, have been evaluated, revealing that the growth-enhancing effects of GHRH are linked to both the dose and the frequency of administration. No unexpected adverse reactions have been observed after extended treatment, regardless of the administration method. Nonetheless, some minor side effects may arise, including fatigue, euphoria (head rush), water retention, and sensations of tingling and numbness. Adhering to the recommended dosage will help reduce the risk of side effects.